Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

AAR reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.01 per share The company ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

Scott Rubner, Citadel Securities' new head of equity and equity derivatives strategy, expects "robust" retail trading flows ...

Netflix (NASDAQ: NFLX) stock rose 0.9% ahead of the release of the latest earnings report from the streaming giant after the ...

US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to ...